Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which immunosuppressive medication blocks the effects of interleukin -2 (IL-2) without inhibiting calcineurin activity?

Sirolimus. ***Sirolimus*** - Sirolimus binds to the **FK-binding protein 12 (FKBP-12)**, forming a complex that specifically inhibits **mTOR (mammalian target of rapamycin)** kinase. - By inhibiting mTOR, it disrupts cell cycle progression from the G1 to the S phase, effectively blocking the **IL-2-mediated signal transduction** pathway without affecting calcineurin. *Tacrolimus* - Tacrolimus acts by binding to **FKBP-12**, but the resulting complex specifically inhibits **calcineurin**. - This inhibition prevents the dephosphorylation and activation of **NFAT (nuclear factor of activated T-cells)**, thereby suppressing IL-2 transcription. *Mycophenolate mofetil* - This drug acts by inhibiting **inosine monophosphate dehydrogenase (IMPDH)**, which is the rate-limiting enzyme in the **de novo synthesis of guanosine nucleotides**. - It primarily targets lymphocyte proliferation by depleting the guanosine pool, rather than interacting with IL-2 pathways or calcineurin. *Azathioprine* - Azathioprine is a prodrug of **6-mercaptopurine**, an antimetabolite that gets converted into thioinosinic acid. - It inhibits **purine synthesis** and DNA replication, causing toxicity to rapidly dividing cells like lymphocytes, but it does not specifically block the IL-2 receptor signaling pathway.

Q: A novel anti-aging compound induces autophagy by inhibiting EP300 histone acetyltransferase, leading to deacetylation of autophagy-related proteins. Which known anti-aging agent works by the same mechanism?

Spermidine. ***Spermidine*** - Spermidine is a naturally occurring polyamine that functions as an **epigenetic modulator** by inhibiting **EP300 histone acetyltransferase**. - This inhibition leads to the **deacetylation** of autophagy-related proteins, which effectively **induces autophagy** and promotes cellular longevity. *Rapamycin* - Rapamycin acts by inhibiting the **mechanistic target of rapamycin (mTOR)** pathway, a highly conserved nutrient-sensing kinase. - Its primary mode of action on autophagy is through the inhibition of mTORC1 rather than modulating histone acetylation. *Metformin* - Metformin exerts its effects primarily by activating **AMP-activated protein kinase (AMPK)**, which regulates cellular metabolism and energy homeostasis. - While it can indirectly upregulate autophagy, it does not function by inhibiting histone acetyltransferases like EP300. *Resveratrol* - Resveratrol functions primarily as an activator of **Sirtuin 1 (SIRT1)**, an NAD+-dependent protein deacetylase. - It promotes longevity through the activation of deacetylases, distinct from the direct inhibition of acetyltransferase activity found with spermidine.

Q: Which of the following is correctly matched (Anti-aging compound - Molecular pathway)?

Metformin - AMPK pathway. ***Metformin - AMPK pathway*** - **Metformin** is a well-studied geroprotector that functions primarily by activating **AMP-activated protein kinase (AMPK)**. - Activation of the **AMPK pathway** mimics the metabolic state of caloric restriction, leading to improved cellular energy homeostasis and insulin sensitivity. *Resveratrol - mTOR inhibition* - **Resveratrol** is primarily known as a **SIRT1 activator**, rather than a direct inhibitor of the **mTOR pathway**. - While it may indirectly influence downstream signaling, its primary recognized mechanism in the context of anti-aging is the modulation of **sirtuins**. *Caloric restriction - Sirtuin (SIRT-1)* - While **caloric restriction** does activate **SIRT1**, the provided pairing is often considered contextually ambiguous or broader in literature compared to the direct pharmacological pathway linkage of metformin and AMPK. - In many standardized formats, this is sometimes presented as a distractor based on the specific primary molecular targets being tested; however, the metformin-AMPK link is the most definitive primary mechanism of action in pharmacology curricula. *Rapamycin - IGF-1/Insulin pathway* - **Rapamycin** acts specifically as a potent inhibitor of the **mTOR complex 1 (mTORC1)**. - While mTOR signaling is downstream of the **IGF-1/Insulin pathway**, characterizing Rapamycin as an IGF-1/Insulin pathway modulator is inaccurate; it is fundamentally an **mTOR inhibitor**.

Q: Identify the type of elimination kinetics represented in the given graph:

First-order kinetics. ***First-order kinetics*** - This process is characterized by the elimination of a **constant fraction** of the drug per unit time, resulting in an **exponential decay** curve on a linear plot. - The rate of elimination is directly **proportional to the plasma concentration** of the drug, meaning faster elimination occurs when drug levels are higher. *Zero-order kinetics* - This involves the elimination of a **constant amount** of drug per unit time, regardless of the plasma concentration. - It typically results in a **linear decline** in plasma concentration over time, often seen when elimination pathways are **saturated**. *Nonlinear kinetics* - This term usually refers to situations where the rate of elimination does not change proportionally with dose, often because the metabolic enzyme systems are **saturated**. - While both zero-order and Michaelis-Menten kinetics are forms of nonlinear elimination, the term is too broad to describe a standard decay curve specifically. *Saturation kinetics* - This describes a state where the capacity of an enzyme or transport system is fully utilized and the system reaches its **maximum velocity (Vmax)**. - When a system becomes saturated at therapeutic levels, it shifts from first-order to **zero-order elimination**.

Q: Calculate the Therapeutic Index of the given drug from the dose-response curve below:

4. ***4*** - The **Therapeutic Index (TI)** is calculated as the ratio of the **Lethal Dose (LD50)** to the **Effective Dose (ED50)**, represented by the formula **TI = LD50 / ED50**. - Given the typical interpretation of such graphs in pharmacology exams, if the ED50 is at 25mg and the LD50 is at 100mg, the calculation 100/25 yields a **Therapeutic Index of 4**. *0.25* - This value represents the **reciprocal** of the correct answer (ED50/LD50), which is incorrect terminology. - A value less than 1 would imply that the **effective dose** is higher than the **lethal dose**, which would make the drug impossible to use safely. *0.75* - This value is not derived from the standard ratio of **LD50** over **ED50** in typical dose-response curve assessments. - It does not correctly reflect the **margin of safety** associated with the drug's therapeutic window. *2* - This result would be obtained if the ratio between the **lethal** and **effective doses** was 2:1. - This likely reflects a misreading of the **x-axis intercepts** for potency or toxicity on the provided graph.

Q: Zero order kinetics is followed by all of the following drugs EXCEPT?

Barbiturates. The core concept here is the difference between **First-order** and **Zero-order kinetics**. Most drugs follow first-order kinetics, where a constant *fraction* of the drug is eliminated per unit time [1]. In contrast, zero-order kinetics occurs when the elimination processes (usually enzymes) become saturated; a constant *amount* of the drug is eliminated regardless of its plasma concentration [1]. **1. Why Barbiturates is the correct answer:** Most **Barbiturates** (like Phenobarbital) follow **First-order kinetics**. Their rate of elimination is proportional to the plasma concentration [1]. While very high doses can lead to saturation, they are classically categorized as first-order drugs in standard pharmacological teaching. **2. Analysis of Incorrect Options (Drugs following Zero-order kinetics):** * **Phenytoin (A):** It follows zero-order kinetics at therapeutic or high concentrations (Michaelis-Menten kinetics). Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity [1]. * **Alcohol/Ethanol (C):** It is the classic example of zero-order kinetics. The enzyme alcohol dehydrogenase is saturated even at low social drinking levels [1]. * **Theophylline (D):** At higher therapeutic ranges, theophylline's metabolism becomes saturated, shifting from first-order to zero-order kinetics. **3. High-Yield Clinical Pearls for NEET-PG:** To remember the drugs following Zero-order kinetics, use the mnemonic **"WATT"** or **"Zero WATTS"**: * **W** – Warfarin (at very high doses) * **A** – Alcohol / Aspirin (at high doses) * **T** – Theophylline * **T** – Tolbutamide * **S** – Salicylates / **S**-Phenytoin **Key distinction:** Zero-order kinetics is also called **"Capacity-limited elimination"** or **"Non-linear kinetics."** In these drugs, the half-life ($t_{1/2}$) is not constant; it increases as the dose increases [1].

Q: If a drug is excreted in urine at the rate of 10 mg/hr at a steady-state plasma concentration of 5 mg/L, then its renal clearance is:

2.0 L/hr. ### Explanation **Concept and Calculation:** Renal clearance ($CL_r$) is defined as the volume of plasma that is completely cleared of a drug by the kidneys per unit of time. It is calculated using the formula: $$CL_r = \frac{\text{Rate of Elimination (Urine)}}{\text{Plasma Concentration (Cp)}}$$ In this question: * **Rate of elimination** = $10\text{ mg/hr}$ * **Steady-state plasma concentration ($C_{ss}$)** = $5\text{ mg/L}$ * **Calculation:** $CL_r = \frac{10\text{ mg/hr}}{5\text{ mg/L}} = \mathbf{2.0\text{ L/hr}}$ **Analysis of Options:** * **Option B (2.0 L/hr) is Correct:** This directly follows the standard clearance formula. * **Option A (0.5 L/hr):** This is an error resulting from dividing plasma concentration by the elimination rate ($5/10$), which is mathematically incorrect. * **Option C (5.0 L/hr):** This value does not correlate with the provided data; it may be a distractor using the plasma concentration value. * **Option D (20 L/hr):** This results from multiplying the two values ($10 \times 2$) instead of dividing them. **NEET-PG High-Yield Pearls:** 1. **Clearance vs. Elimination:** Clearance is a **volume** per unit time (L/hr), whereas the elimination rate is an **amount** per unit time (mg/hr). 2. **Comparison with GFR:** * If $CL_r \text{GFR}$, the drug undergoes **active tubular secretion**. 3. **Loading Dose:** Clearance determines the **Maintenance Dose**, while Volume of Distribution ($V_d$) determines the **Loading Dose**. 4. **First-order Kinetics:** For most drugs, clearance remains constant regardless of plasma concentration.

Question 1

Which immunosuppressive medication blocks the effects of interleukin -2 (IL-2) without inhibiting calcineurin activity?

Accepted Answer

Sirolimus

Answer

Tacrolimus

Answer

Mycophenolate mofetil

Answer

Azathioprine

Question 2

A novel anti-aging compound induces autophagy by inhibiting EP300 histone acetyltransferase,
leading to deacetylation of autophagy-related proteins. Which known anti-aging agent works by the
same mechanism?

Accepted Answer

Spermidine

Answer

Rapamycin

Answer

Metformin

Answer

Resveratrol

Question 3

Which of the following is correctly matched (Anti-aging compound - Molecular pathway)?

Accepted Answer

Metformin - AMPK pathway

Answer

Resveratrol - mTOR inhibition

Answer

Caloric restriction - Sirtuin (SIRT-1)

Answer

Rapamycin - IGF-1/Insulin pathway

Question 4

A 45-year-old chronic smoker is being counselled for smoking cessation therapy. Which of the
following statements regarding nicotine replacement and pharmacotherapy is correct?

Accepted Answer

Acidic beverages should be avoided 15 minutes before using nicotine gum to maximize absorption

Answer

Nicotine patch provides superior efficacy compared to nicotine gum

Answer

Bupropion is associated with more adverse effects than Varenicline

Answer

Varenicline carries a black box warning for cardiovascular toxicity

Question 5

Identify the type of elimination kinetics represented in the given
graph:

Accepted Answer

First-order kinetics

Answer

Zero-order kinetics

Answer

Nonlinear kinetics

Answer

Saturation kinetics

Question 6

Calculate the Therapeutic Index of the given drug
from the dose-response curve below:

Accepted Answer

4

Answer

0.25

Answer

0.75

Answer

2

Question 7

A pharmacology researcher is studying the interaction of a new drug with a receptor system. Two candidate antagonist compounds (Drug X and Drug Y) are tested against a standard agonist at increasing concentrations. The resulting dose-response curves are plotted (Image 1). In the graph, the X-axis represents Log [Agonist Concentration (mol/L)] and the Y-axis represents % Maximum Response (0–100%). Three labeled sigmoid curves are shown: (1) 'Control' — the agonist alone, reaching 100% Emax; (2) 'Drug X + Agonist' — a parallel rightward shift of the control curve with unchanged Emax (~100%); (3) 'Drug Y + Agonist' — a rightward shift with a clearly depressed/lowered Emax (~50–60%). Based on the curves, which of the following statements best describes the mechanism of Drug Y?

Accepted Answer

B. Drug Y binds irreversibly or allosterically to reduce the maximal efficacy of the agonist, and its effect cannot be surmounted by increasing agonist concentration

Answer

A. Drug Y competes reversibly with the agonist at the orthosteric binding site, and its effect can be overcome by increasing agonist concentration

Answer

C. Drug Y acts as a partial agonist, producing a submaximal response that blunts the full agonist curve without shifting the EC50

Answer

D. Drug Y increases the affinity of the agonist for the receptor, producing a leftward shift in the dose-response curve with an elevated Emax

Question 8

Zero order kinetics is followed by all of the following drugs EXCEPT?

Accepted Answer

Barbiturates

Answer

Phenytoin

Answer

Alcohol

Answer

Theophylline

Question 9

If a drug is excreted in urine at the rate of 10 mg/hr at a steady-state plasma concentration of 5 mg/L, then its renal clearance is:

Accepted Answer

2.0 L/hr

Answer

0.5 L/hr

Answer

5.0 L/hr

Answer

20 L/hr

Question 10

A drug with a plasma half-life of 12 hours is administered twice a day. Steady-state plasma concentration reached is 300 mg/dl. Which of the following statements about this drug is not true?

Accepted Answer

Intravenous administration will always achieve a higher concentration than the oral route.

Answer

Plasma concentration will be approximately 260 mg/dl after three half-lives of initiation of therapy.

Answer

After changing the dose, plasma concentration should be measured after 3 days.

Answer

Doubling the dose will double the plasma concentration after 3 days.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?